These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 7608537

  • 1. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
    Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL.
    J Immunol; 1995 Jul 15; 155(2):585-93. PubMed ID: 7608537
    [Abstract] [Full Text] [Related]

  • 2. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.
    Fowler DH, Breglio J, Nagel G, Hirose C, Gress RE.
    Biol Blood Marrow Transplant; 1996 Oct 15; 2(3):118-25. PubMed ID: 9199754
    [Abstract] [Full Text] [Related]

  • 3. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Oct 15; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 4. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.
    Nat Med; 2003 Sep 15; 9(9):1144-50. PubMed ID: 12925844
    [Abstract] [Full Text] [Related]

  • 5. Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease.
    Ewing P, Miklos S, Olkiewicz KM, Müller G, Andreesen R, Holler E, Cooke KR, Hildebrandt GC.
    Exp Hematol; 2007 Jan 15; 35(1):155-63. PubMed ID: 17198884
    [Abstract] [Full Text] [Related]

  • 6. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells.
    Rus V, Svetic A, Nguyen P, Gause WC, Via CS.
    J Immunol; 1995 Sep 01; 155(5):2396-406. PubMed ID: 7650373
    [Abstract] [Full Text] [Related]

  • 7. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR, Majewski D, Ozker K, Hanson G.
    J Immunol; 1998 Sep 01; 161(5):2610-9. PubMed ID: 9725263
    [Abstract] [Full Text] [Related]

  • 8. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
    Jung U, Foley JE, Erdmann AA, Toda Y, Borenstein T, Mariotti J, Fowler DH.
    Biol Blood Marrow Transplant; 2006 Sep 01; 12(9):905-18. PubMed ID: 16920556
    [Abstract] [Full Text] [Related]

  • 9. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S, Kim JC, Whitaker-Menezes D, Murphy GF, Friedman TM, Korngold R.
    Biol Blood Marrow Transplant; 2004 Oct 01; 10(10):669-80. PubMed ID: 15389433
    [Abstract] [Full Text] [Related]

  • 10. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC, Friedman TM, Murphy GF, Korngold R.
    Biol Blood Marrow Transplant; 2004 Feb 01; 10(2):91-105. PubMed ID: 14750075
    [Abstract] [Full Text] [Related]

  • 11. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE.
    J Immunol; 1996 Dec 01; 157(11):4811-21. PubMed ID: 8943383
    [Abstract] [Full Text] [Related]

  • 12. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
    Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR.
    Biol Blood Marrow Transplant; 2006 Nov 01; 12(11):1150-60. PubMed ID: 17085308
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment.
    Fowler DH, Kurasawa K, Husebekk A, Cohen PA, Gress RE.
    J Immunol; 1994 Feb 01; 152(3):1004-13. PubMed ID: 7905495
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM, Waller EK.
    Biol Blood Marrow Transplant; 2004 Aug 01; 10(8):540-51. PubMed ID: 15282532
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.